Working… Menu
Trial record 4 of 8 for:    "Cloacogenic Carcinoma" | "Immunosuppressive Agents"

Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00003596
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : January 4, 2017
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Cancer and Leukemia Group B
Southwest Oncology Group
North Central Cancer Treatment Group
Information provided by (Responsible Party):
Radiation Therapy Oncology Group

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : October 2005
Actual Study Completion Date : December 2016
Publications of Results:
Gunderson LL, Winter KA, Ajani JA, et al.: Long-term update of U.S. GI intergroup RTOG 98-11 phase III trial for anal carcinoma: disease-free and overall survival with RT+5FU-mitomycin versus RT+5FU-cisplatin. [Abstract] J Clin Oncol 29 (Suppl 15): A-4005, 2011.
Ajani JA, Winter KA, Gunderson LL, et al.: Intergroup RTOG 98-11: a phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal. [Abstract] J Clin Oncol 24 (Suppl 18): A-4009, 2006.
Gunderson LL, Winter KA, Ajani JA, et al.: Intergroup RTOG 9811 phase III comparison of chemoradiation with 5-FU and mitomycin vs 5-FU and cisplatin for anal canal carcinoma: impact on disease-free, overall and colostomy-free survival. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-43, S24, 2006.

Other Publications:
Publications automatically indexed to this study by Identifier (NCT Number):